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INTRODUCTION 
Systemic lupus erythematosus (SLE) is a multisystem, autoimmune connective 
tissue disorder with a wide range of clinical features. Dermatological manifestations are 
among the most frequent presenting signs and remain a major source of disease flares 
throughout the course of the illness .1 Assessment of activity of and damage caused by 
cutaneous disease is essential from research as well as practice point of view. Most of the 
indices for systemic activity assessment include cutaneous manifestations as one of the 
components. In 2005, an exclusive index for the cutaneous disease named CLASI 
(Cutaneous lupus area and severity index) was formulated and applied to research .2 
CLASI assesses the activity of and damage caused by cutaneous lupus erythematosus and 
has so far been applied to only LE specific lesions.3 Any given LE patient may manifest 
more than one type of LE-specific skin lesion, but, in most patients one form of LE-
specific skin involvement predominates.1 
 The uniqueness of CLASI lies in its ability to separate damage and activity as 
such a distinction is essential in any disease that can cause severe persistent organ 
damage.  
Systemic activity of lupus can be assessed by numerous indices of which SLEDAI 
(Systemic Lupus Erythematosus Disease Activity Index) is the simplest tool to use .4 It 
grades the activity of the disease from “no activity” to “very high activity”.  Patients with 
LE-nonspecific skin manifestations have significantly increased disease activity 
compared to those with only LE-specific lesions.5 
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AIMS & OBJECTIVES 
1. To study the applicability of  Cutaneous Lupus Erythematosus Disease Area and 
Severity index (CLASI) in specific lesions of cutaneous lupus erythematosus 
occurring in SLE patients in our population.  
2. To assess the disease activity of patients with Systemic Lupus Erythematosus 
(SLE) and skin lesions using the Systemic Lupus Erythematosus Disease Activity 
Index (SLEDAI).  
3. To correlate SLEDAI with CLASI activity score in SLE patients with Lupus 
Erythematosus (LE) specific skin lesions.  
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REVIEW OF LITERATURE 
Cutaneous lupus erythematosus (CLE) is a chronic autoimmune disease with 
specific and non-specific clinical manifestations. While there are indices like SLEDAI 
(Systemic lupus erythematosus disease activity index) 4, BILAG (British Isles Lupus 
Assessment Group) 6 and SLAM (Systemic lupus activity measure) 7 to measure activity 
of systemic disease in SLE, there was, till recently, no exclusive index to measure 
cutaneous activity. 
  CLASI came into existence in 2005 after it was validated in a Philadelphia 
Hospital, USA.2 This index scores damage and activity of the cutaneous disease 
separately. The activity measurement attempts to quantify the level of active 
inflammation in the skin, scalp and oral mucosa. The damage measurement attempts to 
quantify the “footprint” of destruction left behind by the previous inflammation.8 When 
used in routine practice for patient follow up it can provide useful information on the 
response to therapy and for planning new or alteration of existing therapy.  
EPIDEMIOLOGY 
SLE has worldwide distribution, with an estimated prevalence of 12–64/100,000 
population. In most patients, SLE develops between the age of 15 and 45 years. The 
female to male ratio is at least 9:1. In childhood disease, the ratio of girls to boys is 3:1.9 
A review of 32 studies summarized the incidence and prevalence of systemic lupus 
erythematosus in several countries and documented the increased disease burden, 
especially in non-white populations .10 
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A prevalence study in India carried out in a rural population near Delhi found a 
point prevalence of 3 per 100, 000.11 Malaviya et al reported that the median age of onset 
of SLE  was 24.5 years and the sex ratio (F:M) was 11:1.12 In a study done from CMC, 
Vellore that described the clinical profile of 65 patients with LE, the  mean ages of onset 
were 31.3 years in DLE,  33 years in SCLE and 26.8 years in SLE.13  Though the age 
differences were not significant, the male to female ratios of 1.3:1 and 1:7 in DLE and 
SLE respectively were statistically significant. 
CLINICAL CLASSIFICATION OF CUTANEOUS LUPUS ERYTHEMATOSUS 
(CLE) 
Skin lesions are common in SLE and were found in up to 90% of a studied 
cohort.1 
The vast majority of patients will have LE-related skin disease sometime during 
the course of their illness. Discoid lesions, malar rash, oral ulcers and photosensitivity 
constitute 4 of the 11 criteria for the diagnosis of SLE devised by the American College 
of Rheumatology (ACR) in 1982 and modified in 1997.14  There are many patients with 
LE-specific skin disease that do not have, or may never develop SLE.15 
The cutaneous manifestations of lupus are categorized according to the Gilliam 
classification (Appendix A).3 This divides cutaneous lupus erythematosus into LE-
specific and LE-nonspecific skin disease. Specific skin lesions show the distinctive 
histologic change of LE: the interface dermatitis.  LE nonspecific skin lesions are not 
histologically distinct for CLE and may be seen as a feature of another disease process. 
Nonspecific lesions are frequently seen in patients with SLE, usually in the active phase 
of the disease.3 
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LE-SPECIFIC SKIN LESIONS 
Discoid LE (DLE) 
It presents as photo- distributed erythematous papules and / or plaques with 
adherent scaling extending into patulous follicular orifices. Lesions can be localized or 
disseminated.  Localized DLE is confined to the head and neck.  Scalp involvement 
occurs in 60% of DLE patients, and is the only area involved in approximately 10%.16 Of 
patients presenting with DLE lesions, 5% to 10% will subsequently develop clear-cut 
evidence of systemic disease.16 A study describing the clinical profile of 65 patients of LE 
in CMC, Vellore had 32 SLE patients of which 7 patients (21.8%) had DLE lesions.13 
Sub acute cutaneous LE  (SCLE) 
SCLE was first defined by Sontheimer et al.  It presents as non-scarring, 
erythematous, papulosquamous and/or annular skin lesions, occurring in a symmetrical, 
photo distributed pattern.17, 18  Patients presenting with SCLE have accounted for 5–30% 
of variously reported LE populations.19 In the CMC study, 5 out of 65 patients (7.7%) had 
SCLE.13 
Many patients with SCLE fulfill more than four criteria of the American College 
of Rheumatology for SLE.20  
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Acute cutaneous LE (ACLE) 
ACLE can occur as localized or generalized disease. Localized ACLE is often 
referred to as the ‘malar rash’ or ‘butterfly rash’ of SLE.21 There is a tendency to spare 
the nasolabial folds. Generalized ACLE presents as a widespread morbilliform or 
exanthematous eruption in a photo distribution sparing the knuckles and bullous or toxic 
epidermal necrolysis- like acute cutaneous LE skin lesions.3 Usually, the generalized 
form of ACLE is associated with increased disease activity of SLE and is often 
accompanied by mucosal changes affecting the mouth (hard palate, buccal mucosa, 
gingiva, and uvula), nose, pharynx, and vagina. 
Bullous LE 
Bullous LE typically affects young adults in the second, third, or fourth decade of 
life. The criteria utilized for making the diagnosis include the diagnosis of SLE based on 
the ACR criteria, vesicles and bullae arising on, but not limited to, sun-exposed skin and 
routine histopathologic findings compatible with dermatitis herpetiformis.22 
Tumid lupus erythematosus 
It is a distinct entity within the spectrum of chronic CLE. Patients with TLE are 
usually young women who present with nonscarring, photo distributed, indurated, 
violaceous papules and plaques.23 In a study of 15 tumid LE cases,  association with 
systemic disease was found to be  low and the autoantibody profile was negative in 50% 
of the cases, whereas remaining cases had a low titer (<1:160) ANA.23 
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Lupus panniculitis 
Lupus panniculitis occurs frequently in adults between the ages of 20 and 60 years 
(female: male ratio 2:1).24 It usually presents as painful (later asymptomatic) or tender, 
indurated, subcutaneous nodules on the face, proximal extremities and the buttocks. The 
overlying skin may be normal or ulcerated. The nodules may resolve with deeply 
indented scars.21 
Chilblain lupus  
Chilblain or perniotic LE presents as purple red papules, nodules or plaques on the 
toes, fingers and face and is precipitated by cold, damp climates. It is usually seen in 
females.25 
Mucosal  LE 
Cardinali C et al reported a 5.1% prevalence of mucous membrane lesions among 
the 186 SLE patients who were studied for specific skin lesions.27A wide spectrum of oral 
mucosal lesions is found in cutaneous and systemic forms of lupus erythematosus such as 
cheilitis, erythematous patches, discoid lesions, “honeycomb patches”, lichen planus like 
lesions and discrete ulcers.28  
LE-NON-SPECIFIC LESIONS  
The nonspecific lesions are broadly grouped into cutaneous vascular disease, 
nonscarring alopecia and an assortment of other conditions. They are seen only in patients 
with SLE and usually in the active phase of the disease .27 The patients with these lesions 
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have an increased disease activity when compared to those with specific lesions and to 
those with both kinds of lesions.  Cardinali C et al5 found LE non –specific skin lesions in 
31% of the 186 studied patients. The most common non-specific manifestation was 
Raynaud’s phenomenon that was seen in 39.6% followed by nonscarring alopecia seen in 
31% patients.27 
Cutaneous vascular disease  
This includes vasculitis, vasculopathy, periungual telangiectasia, livedo 
reticularis, thrombophlebitis, Raynaud’s phenomenon, and erythromelalgia. 
 Vasculitis: About 10-20% of SLE patients have some form of vasculitis.3 Cutaneous 
vasculitis often correlates with active SLE .29 In the CMC study, purpuric lesions were 
encountered in 20% of SCLE and in 15.6% of SLE patients .13 
Vasculopathy: This may present as atrophie blanche, leg ulcers or Degos disease like 
lesions. It is frequently associated with the presence of antiphospholipid antibodies.3 The 
latter may be associated with livedo reticularis . 
Digital lesions are polymorphous, and often considered clinically as vasculitis. 
These may present as ulceration or gangrene, pitting scars, micro infarcts, urticarial 
lesions, petechiae or purpura, erythematous non tender lesions and nodules .30 
Nonscarring alopecia: Hair loss in SLE is common and may be due to telogen 
effluvium, alopecia areata or lupus hair. Fifty four percent of the patients in one study had 
hair loss .31A positive correlation between diffuse non scarring alopecia and other 
cutaneous features such as malar rash, discoid lesions, photosensitivity and cutaneous 
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vasculitis was found by Wysenbeek AJ et al who studied alopecia in a cohort of 74 SLE 
patients.32 It correlated with exacerbation of disease activity as assessed by disease 
activity index. 
The incidence of alopecia areata was studied in 39 patients by Werth VP et al and 
was found to be 10%.33 It was concluded that alopecia areata may have an association 
with LE. 
Lupus hair is a form of transient alopecia in chronically active SLE patients. Thin, 
weakened hairs are found at the periphery of the scalp especially the frontal area. These 
hairs easily fragment above the surface of the scalp .3, 16 
The other non-specific findings include sclerodactyly, rheumatoid nodules, 
calcinosis cutis, urticaria, LE-nonspecific bullous lesions, lichen planus, erythema 
multiforme and cutis laxa or anetoderma .3 
Antiphospholipid syndrome: It is defined as the occurrence of venous thrombosis, arterial 
thrombosis, recurrent pregnancy loss and /or thrombocytopenia in the setting of moderate 
to high titer lupus anticoagulant or anticardiolipin antibody.1 It may accompany LE or 
may occur as a primary disease.  The cutaneous manifestations include cutaneous 
necrosis, livedo reticularis, superficial thrombophlebitis, digital gangrene, porcelain white 
scars, splinter hemorrhages and ulcerations of the legs.1, 34      
Calcinosis cutis: Though less common, it has been reported in patients with SLE in the 
setting of normal calcium metabolism and renal function. The calcifications are usually 
on the extremities and the overlying skin is prone to ulcerate and extrude calcified 
material.15 
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Cutaneous lupus mucinosis  
It presents as indurated erythematous papules and plaques typically on the arms 
and trunk. The histology shows diffuse dermal mucin deposits but lacks the classic 
vacuolar changes classically seen in LE-specific skin lesions.15 
Pigmented LE  
Cutaneous lupus erythematosus may present as primary pigmented lesions and the 
histopathology of this reveals the picture of DLE.  In the CMC study, 7 patients were 
described who presented with asymptomatic hyperpigmented macules. 13 Biopsy of these 
lesions revealed features of DLE. A retrospective review of cutaneous biopsies in elderly 
patients presenting clinically with single, hyper pigmented macular lesions showed a 
histopathologic correlation .35 
CUTANEOUS LUPUS ERYTHEMATOSUS IN CHILDREN 
The most common clinical features in childhood DLE are discoid plaques and 
photosensitivity.  Cutaneous lesions are usually on the sun-exposed areas .36 
Discoid lupus erythematosus is uncommon in childhood. 36-44 The clinical features 
are similar to those of adults in presentation and chronic course .36  The range of 
histological and immunofluorescence features in children with DLE is similar to that in 
adults .45 
Subacute lupus erythematosus (SCLE) is extremely rare in childhood though a 
few cases have been reported .46-49 
 
 
 
 
 
15
HISTOPATHOLOGY 
DLE: The lesions of DLE show hyperkeratosis with keratotic follicular plugging, variable 
acanthosis and epidermal atrophy. There is basement membrane thickening and an 
interface dermatitis involving the follicles and the epidermis accompanied by a moderate 
to heavy superficial and deep perivascular and periappendageal lymphocytic infiltrate.50,51 
Basal epithelial layer destruction and pigmentary incontinence are characteristic. 
Pronounced dermal mucin deposition is usually present in lesions of DLE .52 
SCLE: The lesions show a mild hyperkeratosis and mild to moderate epidermal atrophy. 
Liquefaction degeneration is usually seen at dermo-epidermal interface and occasionally 
in follicles. Colloid bodies, pigment incontinence, dermal edema and dermal mucinous 
degeneration are occasional.  There is suprabasilar exocytosis of lymphocytes showing 
satellitosis to necrotic keratinocytes.  The interface change exhibits a hybrid pattern 
comprising cell poor vacuolar foci alternating with zones of lichenoid dermatitis. 52  
Bangert et al reported that epidermal atrophy was more common in SCLE in comparison 
to DLE.  They concluded that both DLE and SCLE differ quantitatively in the degrees of 
certain changes.53 The results of this study were confirmed by Mooney E et al.54 
ACLE: The histological changes seen in usually show only discrete interface dermatitis 
with minimal vacuolar alteration of the basal cell layer, upper dermal edema and a sparse 
perivascular mononuclear cell infiltrate .55  Varying mosaics of histological features are 
seen in the 3 major categories of LE-specific disease: acute cutaneous LE (ACLE), 
subacute cutaneous LE (SCLE), and chronic cutaneous LE (CCLE) .56 Lesions of 
generalized acute cutaneous LE can  display histological features of erythema 
multiforme.57  
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In a series of 15 cases of tumid LE that was studied by Alexiades-Armenakas et 
al23 dermo- epidermal junction involvement was absent in 80% of the cases and was focal 
in 20% cases. The hallmark finding present in the study was abundance of mucin in the 
dermis.  
Histology of lupus panniculitis shows lobular panniculitis with a dense 
inflammatory infiltrate of lymphocytes and plasma cells as well as mucin deposits 
between fat cells.21 
Histology of cutaneous lupus mucinosis reveals dermal mucin deposits and 
moderate to severe mononuclear infiltrate around the blood vessels and hair follicles. The 
epidermal and junctional changes of SLE can manifest over a period of time .58 
DIRECT IMMUNOFLUORESCENCE TEST IN CUTANEOUS LUPUS 
ERYTHERMATOSUS 
The test is a valuable adjunct in the diagnosis of SLE when clinical features and 
laboratory investigations are inconclusive .34 
The lupus band test (LBT) describes the presence of immunoglobulins and 
complement components along the dermo-epidermal junction of lesional skin biopsies 
from LE patients.52  IgG, IgM and IGA as well as complement components including 
constituents of membrane attack complex may be deposited.  Non-lesional LBT correlates 
with a more aggressive course of systemic disease including the development of lupus 
nephritis.  It has its greatest utility as a diagnostic test in those with atypical clinical and 
laboratory manifestations of SLE .59 
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In a study in Indian patients, the lupus band test was found to be highly sensitive. 
It was positive for lesional skin of all untreated patients with subacute cutaneous LE and 
systemic LE but was not found useful on nonlesional skin.13 
CUTANEOUS DISEASE ACTIVITY IN SLE 
Appropriate categorization of cutaneous lupus is important for limiting adverse 
outcomes such as scarring as well as in assessing risks for systemic disease .26 A minority 
of patients with DLE will have associated systemic findings, whereas most patients with 
ACLE have aggressive visceral involvement. Patients with SCLE rarely have life-
threatening systemic involvement. Nonspecific skin lesions frequently are seen in patients 
with active disease. They are histopathologically indistinct for LE and may be an 
indicator of disease activity.26 
Therapeutic decisions in cutaneous LE should be based on evaluation of disease 
activity and severity. Severity denotes the gravity of the manifestation while activity 
implies a continuous phenomenon ranging from no activity to maximal activity.7 
The existing outcome measures available for SLE are not sensitive enough to 
measure the activity of CLE. The cutaneous manifestations of SLE are the least 
systematically studied aspects of this illness. General scores like Dermatology index of 
disease severity (DIDS) are too crude in the body surface area assessment in diseases 
which affect relatively small areas of the skin like CLE.60  
A standardized, validated instrument to quantify the level of disease burden or 
improvement in CLE was lacking till 2005 when an index named cutaneous lupus 
erythematosus disease area and severity index (CLASI) came into existence.2 It was 
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designed and validated as an instrument to be used in therapeutic trials in patients with 
CLE. 
CUTANEOUS LUPUS ERTHEMATOSUS DISEASE AREA AND SEVERITY 
INDEX (CLASI) 
This scoring system was developed by investigators at the Veterans Affairs 
Hospital, Philadelphia and the dermatology departments at the University of Pennsylvania 
school of Medicine, Philadelphia and Jefferson Medical College, Philadelphia, USA. The 
design of the CLASI and its characteristics was based on a review of the literature on LE 
and outcome instruments used in dermatology.2 It was assessed for its content validity by 
a group of seven American dermato-rheumatologists and the ACR (American College of 
Rheumatology) Response Criteria Committee on SLE. 
The CLASI has two separate scoring systems for assessing activity of and damage 
caused by cutaneous lupus. This is necessary in any disease that can cause severe 
persistent damage. It facilitates the use of activity in short-term studies whereas damage is 
an important consideration in long term studies where prevention of damage is an 
important factor. 2   This distinct scoring is well established for scores of SLE where 
activity and damage are commonly separated .61 The importance of assigning separate 
activity and damage scores is explained by the fact that a single score that summarizes 
damage and activity cannot provide an exact clinical picture of the disease. In scarring 
forms, as the disease activity decreases and subsequent damage becomes apparent, a 
combined score would remain paradoxically stable despite the change of clinical picture. 
This separation makes both aspects easily quantifiable and assures that CLASI is more 
reactive to therapy induced changes of activity over time.  As current activity or damage 
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may have a significant impact on the quality of patient’s life and self-esteem separate 
damage and activity scores are designed.2 
The area of skin involved by CLE often reflects disease activity and extent of the 
disease .62 The CLASI describes the extent of the disease in terms of the intensity of 
involvement of anatomical areas.  The lesions of CLE are variable in size and may be 
confluent. Disease improvement may lead to division of larger confluent lesions into 
greater number of smaller lesions leading to a paradoxically higher score .2 The area 
involved by CLE is also difficult to calculate as it involves only small areas of the skin in 
contrast to psoriasis and atopic dermatitis where body surface area assessment is used in 
the scores PASI 63 and SCORAD 64,65respectively. Area measurements are often hard to 
reproduce due to inconsistencies in assessment of body surface areas and involved areas 
between investigators.  
The indices that assess skin disease depend primarily on erythema as an indicator 
of skin activity. Erythema is a prominent and easily recognizable sign even in darkly 
pigmented skin.  It is a direct reflection of the hyperemia that accompanies inflammation. 
Though erythema may be under-appreciated in black skin, in the experience of Bonilla—
Martinez Z et al this was not a problem as they applied CLASI in African -American 
patients.66 A trained clinician can readily make out erythema except in the darkest skin 
tones.  The absolute value of erythema due to skin tone is not considered relevant as long 
as the difference in erythema that is attributed to therapy is appreciated.   
CLE affects primarily the visible photosensitive areas.  In CLASI, scalp and the 
face (ears, malar areas and nose, rest of the face) are assigned scores that carry more 
weight through their detailed descriptions. This reflects patient’s concerns through their 
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detailed documentation. DLE often affects only the head, but it can be disfiguring and 
more serious than the widespread SCLE which usually resolves without scarring.   The 
involvement of visible areas causes greater psychological morbidity to patients and needs 
greater therapeutic attention by the physician than that of hidden areas.  The disease 
specific shift is taken into account by the weight placed on visible areas in CLASI.62  
STRUCTURE OF CLASI 2 (Appendix-B) 
CLASI is designed as a table with rows denoting anatomic areas and columns 
include scores for major clinical symptoms.  Separate scores for activity and damage are 
calculated. The activity is assessed by erythema, scale or hypertrophy, mucous membrane 
involvement, acute hair loss and nonscarring alopecia. 
The damage is scored in terms of dyspigmentation, scarring of lesions and/or 
panniculitis and scarring of the scalp.  The dyspigmentation score is doubled if it has 
remained visible for more than 12 months and is taken to be permanent.  
The scores are calculated by simple addition based on the extent of symptoms.  
The severity of involvement for each symptom is calculated according to the worst 
affected lesion within that area for each symptom .2 The maximum possible scores for 
activity and damage are 70 and 56, respectively.8 
The CLASI has been designed as one single instrument for at least three clinical 
entities that constitute CLE i.e. DLE, SCLE and SLE.  The CLASI is not meant to 
document the whole clinical spectrum of CLE. There are some CLE cases that may share 
characteristics of two or even all three groups of CLE.  Future trials in lupus profundus, 
tumid lupus erythematosus or bullous LE may find it necessary to add and evaluate 
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additional subscales to measure the subgroup’s particular characteristics like such as 
bullae and induration.66  
The studies on the applicability of CLASI are limited.  Kreuter A et al recently 
applied the CLASI to a clinical study of 10 patients of SCLE who responded to 
monotherapy with mycophenolate mofetil. The improvement was assessed by CLASI 
over a 3 month follow up, the mean scores falling by statistically significant levels. 19 
Krathen M S et al evaluated the validity CLASI for use by rheumatologists via 
reliability testing.8 They studied 14 subjects of which 10 had cutaneous lupus 
erythematosus, one had a mimicker skin disease only (a cutaneous lesion that may appear 
clinically similar to CLE) and three had both types of lesions.  They were rated with the 
CLASI by academic-based dermatologists and rheumatologists. Reliability testing 
confirmed its use by both dermatologists and rheumatologists.    
Associated subjective symptoms such as pain, pruritus and fatigue as reported by 
the patients are recorded separately on visual 0-10 analog scales. These symptoms are 
important for the assessment of therapeutic success as they are more sensitive indicators 
of disease activity than visual inspection. The relationship of these symptoms to the 
physician assessed symptoms is unclear and hence they are not integrated with the CLASI 
score .2 Bonilla-Martinez Z et al showed that the CLASI activity correlated well with the 
physicians’ and patients’ global assessment of the disease activity on a 0 to 10 visual 
analogue scale. 66 
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DISEASE ACTIVITY INDICES IN SLE 
Disease activity is defined as a reversible manifestation of an underlying 
inflammatory process. It reflects the type and severity of organ involvement at each point 
in time. Assessment of disease activity is very important as many treatment decisions 
depend on the accuracy of the physician’s clinical judgment of disease activity.4 In 
clinical practice, concepts of both activity and severity are used to evaluate patients. 
Activity implies a continuous phenomenon (an interval scale) ranging from no activity to 
maximal activity. Severity implies gravity of the manifestation.67 
About 60 consensual systems were developed and applied by rheumatologists to 
quantify systemic disease activity in their patients with SLE. Of these the SLEDAI 
(Systemic Lupus Erythematosus Disease Activity Index) 4  BILAG (The British Isles 
Lupus Assessment Group)6 and the SLAM (Systemic Lupus Activity Measure)7 designed 
to assess systemic activity of LE appeared useful for dermatological needs. Goodfield M 
et al pointed that these indices are more in favour of systemic manifestations.61 Hence 
there was need to establish criteria that are more suitable to characterize the disease 
specific parameters of cutaneous LE. 
The indices have been shown to be valid when used by physicians from different 
countries. The reproducibility, validity and sensitivity to change of these commonly used 
indices have been confirmed.68 
SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY INDEX (SLEDAI) 
(Appendix C)4 
SLEDAI was developed by  Bombardier C et al  at the University of Toronto.4 It is 
a global index containing 24 weighted objective clinical and laboratory variables and 
 
 
 
 
 
23
measures disease activity within the last 10 days. The advantage of SLEDAI is the 
relatively small number of items and the ease of scoring. 
It is designed as a one page weighted form consisting of 24 items. An item is 
noted when present in a patient. The score is calculated by summing the predetermined 
weights for the items that are present.  Life threatening items are assigned higher weights. 
The maximum possible score is 105. It includes immunology results in the form of 
positive scoring for an abnormal level of anti-dsDNA antibodies or complement (C3 or 
C4). The mucocutaneous manifestations that are scored are a new onset inflammatory 
rash, mucosal ulcers, alopecia and vasculitis. The latter includes ulceration, gangrene, 
tender finger nodules, periungual infarction and a biopsy proof of vasculitis. 
Systemic disease activity categories have been defined on the basis of SLEDAI 
scores: no activity (SLEDAI = 0), mild activity (SLEDAI = 1-5), moderate activity 
(SLEDAI = 6-10), high activity (SLEDAI = 11-19), and very high activity (SLEDAI 20 
and above).69   Fitzgerald J D  applied SLEDAI in a retrospective chart study and showed 
that disease activity can be reliably reproduced through such study.70 
A study from Spain by Formiga et al applied SLEDAI at the moment of diagnosis 
of SLE and during the first year of the disease in 100 patients. It was found that lupus in 
the older age group is a distinct clinical entity with a severe course at presentation and 
during the first year of the disease.71 Zecevic RD et al applied SLEDAI in a correlation 
study between specific and nonspecific lesions. They found that patients with LE non-
specific skin lesions had significantly high SLEDAI scores.5 
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PATIENTS AND METHODS 
The study was conducted from 1st May 2007 to 30th August 2008 (16 months). It 
was a prospective, cross sectional study done in the Department of Dermatology, 
Venereology and Leprosy. The subjects were those attending the outpatient department 
and inpatients referred to us from the Medical, Pediatrics and rheumatology units. 
Inclusion Criteria: 
1. All patients with systemic lupus erythematosus having  lupus specific and non-
specific lesions.3 
Exclusion Criteria: 
1. Patients without a cutaneous manifestation of LE. 
2. Patients not willing to be included. 
3. Neonatal lupus. 
Ninety-three patients with a diagnosis of SLE according to the 1997 modification 
of ARA criteria 14 (Appendix D) were included in the study. Three patients were excluded 
as they were subsequently diagnosed to have mixed connective tissue disease. 
Patients were examined by the principal investigator. A detailed proforma was filled 
(Appendix E). The demographic data included age, address, gender and occupation.   
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The presenting mucocutaneous complaints and their respective durations were 
noted.  The body sites affected by lupus specific and non-specific manifestations were 
recorded.  A history of drug intake (corticosteroids, immunosuppressants and 
hydroxychloroquine) and the topical applications used by the patient in the three months 
prior to their presentation was noted. Subjects were informed about the purpose of the 
study (Appendix F) and informed consent (Appendix G) was obtained.  Separate child 
and adolescent assent forms (Appendices H1 & H2) were used for patients in the age 
groups of 7- 12 years and 13-17 years respectively.  Clinical photographs of lesions were 
taken after patient consent or parenteral consent in case of children. 
Clinical Examination 
Each patient was examined by the principal investigator for skin lesions.  They 
were classified as specific or non-specific according to the Gilliam classification 
(Appendix A) 3 for skin lesions of LE.  The diagnosis of CLE was based on clinical 
features and confirmed by skin biopsy, whenever necessary. The lupus specific lesions of 
acute, subacute and chronic cutaneous lupus erythematosus were recorded. Cutaneous 
vascular lesions such as palpable purpura, urticarial vasculitis, Raynaud’s phenomenon as 
well as other non-specific manifestations were recorded in the proforma.   
Laboratory investigations 
These included a hemogram, urine microscopy, urine albumin, 24 hour urine protein, 
antinuclear antibody (ANA), serum complement,  C3 and C4 estimation, and anti-double 
stranded DNA (anti dsDNA). 
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Skin biopsy and Direct immunofluorescence (DIF) test 
Biopsy of the lesional skin for histopathology was done whenever necessary. The 
histological features were classified as specific, non-specific and equivocal.  It was 
reported as specific if it showed characteristic features of LE as reported by Lever.50 If the 
histological features were highly suggestive, but not characteristic, they were classified as 
equivocal. The term nonspecific was used when features were not suggestive of LE. 
For direct immunofluorescence (DIF) the skin biopsy samples were freshly 
frozen. Cryostat sections were immunostained by the DIF method using antibodies to 
IgG, IgA, IgM and C3.  It was considered positive if it showed multiple immunoreactants 
(inclusive of IgG) at the basement membrane zone in a granular or linear pattern. 
 Scoring of the CLASI (Appendix B) 
The activity and the damage scores of specific lesions of CLE were calculated 
using the physician rating.  The maximum possible CLASI activity and damage scores are 
70 and 56 respectively. 
 Thirteen anatomical sites were examined for the most severely affected cutaneous lupus-
associated lesion. 
Scoring of activity 
Activity was assessed by examination of erythema, scale/hypertrophy, mucous 
membrane disease, acute hair loss, or no scarring alopecia.  Erythema was graded on a 
scale of 0-3 from its absence to dark red/purple/violaceous/crusted/hemorrhagic lesions.  
Scaling was graded on a 0-2 scale, from absent scaling to verrucous or hypertrophic 
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lesions.  Mucous membrane involvement was recorded as present or absent.  Acute hair 
loss was defined as occurring within the last 30 days or as reported by the patient.  Scalp 
alopecia was graded on a scale of 0-3 from absent alopecia to alopecia that was focal or 
patchy in more than one scalp quadrant. 
For the purpose of defining a scalp quadrant, the scalp was divided by two 
intersecting lines-one connecting the highest points of both ear lobes and  an imaginary 
line running through the midline of the scalp dividing it into right and left halves. If there 
was a lesion within the quadrant, the same was considered as involved. 
The total activity score was calculated by summation of the scores of erythema, 
scale, mucosal involvement and alopecia.  
Scoring of damage 
Damage was assessed by noting dyspigmentation, scarring/atrophy, and scarring 
alopecia. These parameters were assessed in similar body locations as in the activity 
assessment.  
Dyspigmentation was noted as present or absent. If the dyspigmentation lasted at 
least 12 months, the score of the same was doubled.  Scarring and/or atrophy were graded 
from absent to severely atrophic scarring or panniculitis on a 0 to 2 scale. Scalp scarring 
was graded on a 0 to 6 scale from absent scarring to involvement of the whole skull. 
If a particular scalp lesion had both scarring and non-scarring alopecia, both were 
scored independently. 
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The total damage score was calculated by the summation of the score for 
dyspigmentation, scarring of skin and scarring alopecia. 
Systemic lupus erythematosus disease activity index (SLEDAI) (Appendix C)4 
SLEDAI was used to assess the systemic disease activity. Apart from the central 
nervous system manifestations of the disease(seizures, psychosis, cranial nerve disorder, 
lupus headache and cerebrovascular accident), patients were examined for leg and digital 
ulcers, gangrene, tender finger nodules, joint swelling or tenderness and questioned about 
proximal muscle ache or weakness. Biopsy proof of vasculitis was recorded. Urine 
analysis findings of hematuria, proteinuria, pyuria and casts were noted. Cutaneous 
manifestations scored for the purpose of SLEDAI were: new onset inflammatory rash, 
new onset or recurrence of oral or nasal mucosal ulcers and new onset or recurrence of 
diffuse or patchy hair loss.  Laboratory findings noted were total leukocyte counts, 
platelet counts, total complement and C3, C4 levels and estimation of double stranded 
DNA antibodies. 
Each of the 24 items on the SLEDAI scoring system was recorded according to 
their presence or absence at the first patient visit or in the previous ten days. These items 
were given the pre-assigned scores.  The individual scores were added to give the total 
SLEDAI score. Activity categories were defined on the basis of SLEDAI scores from no 
activity (SLEDAI = 0) to a high activity (SLEDAI 20 and higher).69 
The maximum SLEDAI score possible is 105. 
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Statistical analysis 
The variables analyzed were the CLASI activity score, CLASI damage score, 
SLEDAI score, duration of SLE and the duration of the skin lesions.  Nonparametric 
correlation (Spearman correlation coefficient) was done to study the correlation between 
CLASI activity scores and the SLEDAI scores as well as the correlation of the CLASI 
damage score with the duration of the disease and the duration of skin lesions. Linear 
regression analysis was done to quantify the relationship between duration of the disease 
and of the skin lesions and the CLASI damage score. 
The study was approved by the Ethics committee of the Institutional Review 
Board. 
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RESULTS 
TABLE 1- AGE AND GENDER OF THE PATIENTS 
Age   
(years) 
Males  
(n=6) 
Females 
(n=87) 
Total Number 
(n=93) 
Percentage  
(%) 
5-9 0 1 1 1.07 
10-19 1 14 15 16.12 
20-29 2 34 36 38.70 
30-39 2 17 19 20.43 
40-49 1 12 13 13.97 
50-59 0 6 6 6.45 
>60 0 3 3 3.22 
Demographic profile   
Ninety- three patients met the inclusion criteria of the study.  Three patients were 
excluded as they were subsequently diagnosed to have mixed connective tissue disease. 
The majority of patients were from West Bengal (40.9%), the southern states of 
Tamilnadu, Andhra Pradesh and Kerala (29%) and Jharkhand (10.75%).   The remaining 
patients (19.3%) were mostly from the North Eastern and other Indian states and 
Bangladesh. 
Age and gender (Table 1) 
  There were 87 adults (>15 years) and 6 children (≤ 15 years). The mean age of the 
patients was 29.8±12.73 years (range 5-65). There were 87 females and 6 males.   The 
mean age of males was 28.5±10.46 years (range 13-40) and that of females was 29.9 
±10.46 years (range 5 -65). The male to female ratio was 1:14.5 and 1:5 among adults and 
children respectively. 
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Clinical profile 
TABLE 2-PRESENTING COMPLAINTS 
Presenting 
complaints 
Number of patients 
(n=93) 
Percentage 
(%) 
Mean duration 
(Months) 
Alopecia 67 72% 12.17 
Photosensitivity 64 68% 14.3 
Oral ulcers 57 61% 9.73 
Skin lesions 31 33.3% 10.58 
 
Presenting complaints (Table 2) 
The most common presenting complaint was alopecia (67 patients; 72%) followed 
by photosensitivity (64 patients; 68%) and oral ulcers (57 patients; 61%). Skin lesions 
were the first manifestation in 31 patients (33.3%). 
The most common site for skin lesions was the face (85%) followed by involvement of 
the trunk (75%) and the upper limbs (70%). 
The mean duration of SLE at presentation was 31.9 months (range 2-228 months; 
SD 42.11) and the mean duration of skin lesions was 12 months (range 0.25 -84 months; 
SD 16.20) 
 
 
 
 
 
32
TABLE 3-TYPES OF SKIN LESIONS ON GILLIAM’S CRITERIA3 
Type of skin lesions  in 
patients 
Number of patients 
(n=93) 
Percentage 
(%) 
Specific skin lesions 19 20.43 
Non-specific skin lesions 17 18.28 
Specific and non-specific 
skin lesions 
56 60.21 
 
Classification of skin lesions based on Gilliam’s criteria (Table 3) 
More than half the patients (60.21%) presented with a combination of specific and 
non-specific lesions while 19 (20.43%) had only specific and 17 (18.28%) had only non-
specific lesions. Specific lesions of LE alone or in combination with non-specific lesion 
of LE were observed in 75 (80.65%) patients. 
TABLE 4-TYPES OF SPECIFIC LESIONS  
Type of specific lesion Number of patients (n=93) Percentage         
(%) 
Discoid lesions 51 54.83 
Malar rash 29 31.19 
Generalised acute cutaneous 
LE 26 27.96 
Papulosquamous 
rash(SCLE) 7 7.53 
Tumid lesions 4 4.31 
Panniculitus 1 1.08 
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LE-specific skin lesions (Table 4) 
The most common specific cutaneous lesions were discoid lesions that were seen 
in 51(54.83%) patients followed by malar rash in 29 patients (31.19%) and generalised 
acute cutaneous LE in 26 patients (27.9%). Papulosquamous lesions of subacute lupus 
erythematosus (SCLE) were seen in 7.53% patients. 
TABLE 5-TYPES OF NON-SPECIFIC LESIONS  
Non-specific lesions Number of patients Percentage 
Alopecia±Lupus hair 59 63.44 
Mucosal ulcers 39 41.93 
Palpable purpura 18 19.36 
Targetoid lesions 9 9.68 
Livedo reticularis 7 7.53 
Raynaud’s phenomenon 4 4.31 
Leg ulcers 3 3.23 
Digital ulcers 3 3.23 
Urticaria 2 2.15 
Alopecia areata 1 1.08 
Sclerodactyly 1 1.08 
Bullous lesions 1 1.08 
Finger nodules 1 1.08 
Urticarial vasculitis 1 1.08 
 
LE non-specific skin lesions (Table 5) 
Among the non-specific lesions, alopecia (63.44%) was the most common followed by 
mucosal ulcers (41.93%) and palpable purpura (19.36 %). 
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TABLE 6 - HISTOPATHOLOGY AND DIRECT IMMUNOFLUORESCENCE 
FEATURES OF SPECIFIC AND NON-SPECIFIC LESIONS 
S.No. Clinical HPE DIF 
1 Ulcer/purpura Stasis dermatitis/LCV Perivascular IgA and C3 
2 GACLE Erythema multiforme like Negative 
3 DLE Specific ----- 
4 GACLE Equivocal IgM only 
5 Tumid lesion Non-specific ----- 
6 GACLE Non-specific Positivity of BM for IgG,M and C3 
7 Purpura LCV -------- 
8 DLE Equivocal Positivity of BM for IgG, A, M and  C3 
9 Papulosquam lesions SCLE Specific -------- 
10 Leg ulcer Inadequate --------- 
11 Purpura LCV -------- 
12 Ulcer Non-specific ------- 
13 GACLE Non-specific Positivity of BM for IgG, IgA, IgM and  C3 
14 GACLE Non-specific Positivity of BM for IgG, IgA, IgM and  C3 
15 Malar rash Equivocal C3 only 
16 DLE Non-specific ------- 
17 DLE Equivocal ------- 
18 Targetoid Non-specific -------- 
19 GACLE Equivocal --------- 
20 Discoid Specific -------- 
21 Purpura LCV Negative 
22 Discoid 
Perifollicualr and 
perivasular 
inflammation 
-------- 
23 Nodules Panniculitis ---------- 
24 Discoid Specific Positivity of BM for IgG, IgA, IgM and  C3 
25 Hypopigmented macules Non-specific ---- 
26 DLE Non-specific C3 only 
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(Contd…) 
S.No. Clinical HPE DIF 
27 DLE Specific Positivity of BM for IgG, IgA,IgM and  C3 
28 Malar rash Specific ----------- 
29 Cutaneous vasculitis LCV ----------- 
30 GACLE Erythema multiforme like 
Fine granular staining for 
IgG, IgM and C3 
31 Purpura LCV --------- 
32 GACLE ACLE Fine gran discon stainfor IgG,,IgM , IgA and C3 
33 GACLE Erythema multiforme like 
Coarse gran positivity of 
BM for IgG, IgM and  C3 
34 Lupus mucinosis ACLE 
Fine gran positivity of BM 
for IgG, IgA, IgM and  C3 
35 DLE DLE --------- 
36 Purpura LCV ---------- 
37 Ecchymosis Non-specific ----------- 
38 GACLE Specific Fishnet fluorescence for IgG 
39 Malar rash Non-specific --------- 
40 Malar/GACLE Non-specific --------- 
41 Purpura LCV 
Thick linear deposits of 
IgG,M and A in BMZ  and 
IgG on vessel wall 
42 Discoid Non-specific IgM only 
43 Malar rash Equivocal IgM only 
44 Discoid Specific --------- 
45 Discoid Specific Specific IgA,IgG and C3 
46 GACLE Erythema multiforme like Negative 
47 Malar rash Non-specific ------- 
48 GACLE Specific  
49 GACLE ACLE Negative 
DLE-Discoid lupus erythematosus, LCV-leucocytoclastic vasculitis, GACLE-Generalise acute cutaneous 
LE, ACLE-Acute cutaneous lupus erythematosus, papulosquam-papulosquamous lesions, SCLE-Sub acute 
cutaneous lupus erythematosus,BM-Basement membrane 
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Results of histopathology and DIF (Table 6) 
Skin biopsy of the representative skin lesion was done in 49 out of 93 (52.68%) 
patients.  Biopsies were done from 35/49 patients with LE specific lesions. Twenty -four 
out of the 35 (68.5%) patients showed histological features of LE and 11/35 (31.42%) 
patients showed non- specific features. 
DIF was done in 23 (24.73%) patients, 19 of whom had clinically specific and 4 
had clinically non-specific lesions. Of the 19 patients, 14 patients had histologic features 
of LE and 5 patients had non-specific histology. DIF was positive in 10 patients (7 with 
specific and 3 with non-specific histology). 
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TABLE 7-PHYSICIAN RATED CUTANEOUS LUPUS ACTIVITY SCORE IN 74 
PATIENTS WITH SPECIFIC SKIN LESIONS OF SLE AND THEIR 
RESPECTIVE SLEDAI SCORES 
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1 42/F Discoid N Y Y(1) 3 7 7 
2 21/F Discoid N Y Y(1) 7 12 29 
3 21/F Discoid N Y Y(3) 10 19 15 
4 65/F Discoid Y Y Y(1) 10 22 19 
5 13/F 
Discoid 
/GACLE Y Y Y(1) 9 14 17 
6 35/F 
PLR/(Tumid 
lesions) Y N Y(1) 7 11 20 
7 22/F 
Discoid 
/GACLE Y Y Y(3) 11 24 20 
8 17/F 
Discoid 
/GACLE Y Y Y(3) 13 29 28 
9 33/F Discoid/malar N Y N(0) 4 10 17 
10 26/F 
Discoid 
GACLE/papsq
uam 
Y Y Y(1) 6 15 15 
11 52/F Discoid N N Y(1) 1 2 4 
12 54/F 
Discoid 
/papsquam N Y Y(1) 4 8 12 
13 18/F 
Malar 
rash/GACLE Y Y Y(1) 7 17 24 
14 17/F 
Discoid 
/GACLE Y Y Y(1) 6 11 19 
15 32/F GACLE N N Y(1) 8 10 15 
16 55/F Discoid N Y Y(1) 4 9 6 
17 18/F Discoid N Y Y(1) 1 4 2 
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18 57/F Malar N Y Y(1) 2 3 20 
19 31/F Papsquam N Y Y(1) 10 26 8 
20 20/F Discoid N Y Y(3) 3 9 6 
21 24/F 
Malar 
/GACLE Y Y Y(1) 4 10 19 
22 18/F 
Discoid 
/Malar 
/papsquam 
Y 
 Y Y(1) 11 28 23 
23 34/F 
Malar 
/GACLE Y Y Y(1) 6 22 23 
24 27/F Discoid N Y Y(1) 6 14 2 
25 30/F 
Malar  
/Papsquam Y Y Y(1) 7 20 16 
26 25/F Discoid Y Y Y(1) 7 15 13 
27 24/F 
Discoid 
/Malar N Y Y(1) 3 7 6 
28 22/F Discoid N N N(0) 6 6 14 
29 20/F Discoid N N N(0) 2 4 2 
30 34/F 
Discoid 
/Malar Y Y Y(1) 8 20 8 
31 16/F 
Discoid 
l/Malar N Y Y(1) 8 21 8 
32 23/F Discoid Y Y Y(1) 12 37 10 
33 46/
F 
Discoid N Y Y(1) 4 11 12 
34 16/
F 
Malar 
rash/GACLE 
Y N N(0) 11 22 4 
35 32/
F 
Discoid 
lesions 
Y Y Y(1) 9 27 10 
36 23/
F 
Discoid 
lesions 
N Y Y(3) 9 27 10 
37 12/
F 
Malar 
rash/Discoid 
lesions 
N Y Y(1) 3 8 4 
(Contd…) 
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38 20/
F 
Malar 
rash/GACLE 
Y Y Y(1) 11 28 12 
39 30/
F 
GACLE Y Y Y(1) 8 17 30 
40 19/
F 
Discoid/GAC
LE 
N Y Y(1) 5 11 12 
41 27/
F 
Malar/GACLE Y Y Y(1) 9 22 17 
42 20/
F 
Malar/GACLE N Y Y(1) 9 15 6 
43 20/
F 
Discoid Y Y Y(1) 5 13 4 
44 38/
M 
Malar/GACLE Y N N(0) 13 30 22 
45 30/
F 
Malar/GACLE Y Y Y(1) 10 22 12 
46 20/
F 
Discoid Y Y Y(1) 1 4 28 
47 26/
F 
Malar/Discoid Y Y Y(1) 3 10 22 
48 61/
F 
Discoid/GAC
LE 
Y Y Y(1) 11 29 20 
49 28/
F 
Discoid N Y Y(3) 2 5 4 
50 46/
F 
Papsquam Y Y Y(1) 7 20 10 
51 36/
F 
Discoid N Y Y(1) 1 4 10 
52 12/
F 
GACLE Y Y Y(1) 12 15 15 
53 44/
F 
Discoid 
lesions 
Y N N(0) 9 25 12 
54 15/
F 
Malar rash N Y Y(1) 2 5 32 
55 22/
F 
Malar/GACLE N Y Y(1) 6 13 18 
56 13/
F 
Discoid N Y Y(1) 1 4 6 
57 63/
F 
Discoid N Y Y(1) 11 28 9 
58 47/
F 
Malar/Discoid Y Y Y(1) 3 6 16 
(Contd…) 
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59 21/
F 
Malar/GACLE
/Discoid 
Y Y Y(1) 13 36 8 
60 20/
M 
Malar/discoid N N N(0) 5 10 6 
61 40/
F 
Discoid Y Y Y(3) 5 12 4 
62 40/
F 
Papsquam/disc
oid 
N N Y(1) 9 16 6 
63 37/
F 
Malar/(Tumid) N Y Y(1) 2 10 6 
64 32/
M 
Discoid N N N(0) 3 4 17 
65 26/
F 
Discoid N Y N(0) 10 26 8 
66 28/
M 
Malar N Y N(0) 1 3 25 
67 28/
F 
Malar/GACLE Y Y Y(1) 11 26 10 
68 42/
F 
Discoid Y Y Y(1) 3 10 15 
69 31/
F 
Discoid Y Y Y(1) 9 23 19 
70 22/
F 
Malar  N N N(0) 1 2 6 
71 52/
F 
Discoid/GAC
LE 
Y Y Y(1) 8 19 10 
72 23/
F 
Malar/GACLE
/Discoid 
Y Y Y(1) 9 24 20 
73 38/
F 
Malar/GACLE
/Discoid 
Y Y Y(1) 13 39 14 
74 25/
F 
Discoid Y N N(0) 4 8 17 
 
GACLE---Generalised acute cutaneous lupus erythematosus, Discoid-Discoid lesions, Malar-Malar Rash, 
Papsquam-  Papulosquamous lesions,Y-Yes, N-No 
Grades of clinical nonscarring alopecia: Grade 0-Absent, Grade 1-diffuse,non-inflammatory, 2-focal or 
patchy in one quadrant, 3-focal or patchy in more than one quadrant 
 
 (Contd…)  
 
 
 
 
 
Physician rated CLASI activity score (Table 7) 
CLASI activity was scored for the 74/93 (79.56%) patients with specific lesions.  
Mean CLASI activity score was 15.6±9.28 (range 2-39; maximum score =70) 
The average number of sites scored was 6.58 (range 1 to 13).  The CLASI activity 
score was ≥20 in 27 patients of whom 15 (55.5%) patients had 10 or more sites of 
involvement. There was a trend towards increasing activity scores in patients with higher 
number of involved sites.  
Fifty- one patients (68.9%) had discoid lesions, 41(55.4%) patients had lesions of 
acute cutaneous LE and 7 (9.45%) patients had papulosquamous lesions of subacute 
cutaneous LE. Twenty- three (31.08%) patients had more than one type of LE specific 
skin lesions.   
Mucosal involvement was seen in 39 (52.7%) patients. Sixty-one (82.43%) 
patients had self reported alopecia. Nonscarring alopecia was clinically seen in 62 
(83.78%) patients.  
Most of the patients had an associated alopecia or oral mucosal involvement. 
Specific cutaneous lesions without alopecia or oral mucosal involvement were 
exclusively seen in 5 (6.75%) patients. 
Grade 1 erythema (pink, faint erythema) was seen in 56.59% of the patients. 
Grade 2 (red) and grade 3 (dark red, crusted, hemorrhagic) erythema was seen in 34.54% 
and 8.86% patients respectively.  Erythema was most commonly observed in lesions of 
the face and the ears. On the face, 46.67% had grade 1 erythema, 40% had Grade 2 
 
 
 
 
 
erythema and 13.33% had a grade 3 erythema.  Erythema was less frequent on the 
covered areas (legs, feet, and abdomen). 
Grade I scaling was most commonly observed on the ear and facial lesions 
(100%) followed by those on the scalp (97.5%). Grade II scaling was observed in 5 
(6.75%) patients.  
TABLE 8- MORPHOLOGY OF THE LESIONS AND THE CLASI ACTIVITY 
SCORES 
Types of lesions(n=74) Mean CLASI activity score 
SCLE(n=2) 23 
ACLE/DLE/SCLE(n=2) 21.5 
ACLE/SCLE(n=1) 20 
ACLE/DLE(n=18) 18.22 
ACLE(n=20) 15.15 
DLE(n=29) 13.48 
DLE/SCLE(n=2) 12 
 
Morphology of the skin lesions and CLASI activity scores (Table 8) 
There was a relationship between the morphology of the lesions and mean CLASI 
activity scores.  Patients with SCLE, and ACLE occurring with other types of LE specific 
lesions had higher activity scores than those with only discoid lesions or ACLE.  
The mean activity score for patients who had only specific skin lesions without mucosal 
involvement or alopecia was 5.2 and the average number of sites affected was 3.4. 
 
 
 
 
 
TABLE 9: CLASI damage score, duration of SLE and the duration of skin lesions 
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1 42/F 36 36 12/0 Y(12) Y(1) N(0) 12 13 
2 21/F 4 4 5/1 Y(6) N(0) N(0) 6 6 
3 21/F 36 5 0/1 Y(1) N(0) Y(6) 1 7 
4 65/F 30 30 1/0 Y(1) N(0) N(0) 1 1 
5 13/F 6 6 3/0 Y(2) Y(1) N(0) 3 3 
6 35/F 8 1.5 2/1 Y(3) N(0) N(0) 3 3 
7 22/F 24 3 6/1 Y(7) Y(1) Y(4) 7 11 
8 17/F 60 60 7/1 Y(8) Y(3) Y(5) 8 27 
9 33/F 24 1 3/0 Y(3) Y(1) N(0) 3 8 
10 26/F 4 1 1/0 Y(1) N(0) N(0) 1 
 
1 
11 52/F 36 36 8/1 Y(9) N(0) N(0) 9 18 
12 54/F 12 8 9/1 Y(10) N(0) N(0) 10 10 
13 17/F 6 24 5/0 Y(5) Y(3) N(0) 5 8 
14 55/F 48 12 3/0 Y(3) N(0) N(0) 3 3 
15 31/F 24 12 3/1 Y(4) N(0) Y(6) 4 14 
16 20/F 24 24 2/1 Y(3) N(0) Y(5) 3 11 
17 24/F 3 3 2/0 Y(2) N(0) N(0) 2 2 
18 18/F 8 10 8/1 Y(9) N(0) N(0) 9 9 
19 27/F 36 36 8/1 Y(9) Y(1) Y(5) 9 25 
20 30/F 12 12 4/0 Y(4) N(0) N(0) 4 8 
21 24/F 6 6 1/0 Y(1) N(0) N(0) 1 1 
22 32/F 6 4 4/0 N(0) Y(4) N(0) 4 8 
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23 22/F 3 0.75 6/0 Y(5) Y(1) N(0) 6 10 
24 20/F 24 1 2/0 Y(2) Y(2) N(0) 2 8 
25 34/F 60 60 11/1 
 
Y(12) N(0) N(0) 12 24 
26 16/F 24 24 2/0 Y(2) N(0) N(0) 2 4 
27 23/F 48 48 3/1 Y(4) N(0) Y(5) 4 13 
28 46/F 120 36 2/1 Y(3) N(0) Y(4) 3 10 
29 16/F 3 0.5 1/0 Y(1) N(0) N(0) 1 1 
30 32/F 6 6 7/0 Y(7) N(0) N(0) 7 7 
31 23/F 18 18 6/1 Y(7) N(0) Y(6) 7 30 
32 20/F 6 6 2/0 Y(2) N(0) N(0) 2 2 
33 30/F 10 1 1/0 Y(1) N(0) N(0) 1 1 
34 19/F 6 0.5 1/0 Y(1) N(0) N(0) 1 1 
35 27/F 36 1 1/0 Y(1) N(0) N(0) 1 1 
36 20/F 6 1 9/1 Y(5) Y(7) Y(6) 10 18 
37 38/
M 
3 3 1/0 Y(1) N(0) N(0) 1 1 
38 20/F 6 2 1/0 Y(1) N(0) N(0) 1 1 
39 26/F 6 1 4/0 Y(3) Y(1) N(0) 4 4 
40 61/F 60 0.5 3/1 Y(4) Y(2) Y(4) 4 14 
41 28/F 2 1.5 11/1 Y(12) N(0) Y(4) 12 16 
42 46/F 6 6 2/1 Y(3) N(0) Y(6) 3 9 
43 36/F 132 3 1/0 Y(1) Y(1) N(0) 1 2 
44 44/F 120 9 8/1 Y(6) Y(5) Y(6) 9 28 
45 22/F 3 0.75 1/0 Y(1) N(0) N(0) 1 1 
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46 13/F 24 24 1/0 Y(1) N(0) N(0) 1 1 
47 63/F 24 12 3/1 Y(3) Y(2) N(0) 4 5 
48 47/F 36 36 8/1 Y(9) N(0) N(0) 9 18 
49 21/F 12 12 1/1 Y(2) N(0) N(0) 2 4 
50 40/F 84 84 2/1 Y(3) Y(3)  Y(6) 3 13 
51 32/M 2 2 2/0 Y(2) N(0) N(0) 2 2 
52 26/F 42 42 4/0 Y(4) Y(2) N(0) 4 10 
53 28/F 2 1 1/0 Y(1) N(0) N(0) 1 1 
54 42/F 6 6 1/0 Y(1) N(0) N(0) 1 1 
55 31/F 6 6 8/1 Y(9) N(0) N(0) 9 9 
56 52/F 2 2 7/0 Y(7) N(0) N(0) 7 7 
57 23/F 8 1 5/0 Y(5) N(0) N(0) 5 5 
58 38/F 6 0.5 5/0 Y(5) N(0) N(0) 5 5 
59 25/F 2 2 1/1 Y(2) N(0) N(0) 2 2 
 
CLASI damage score (Table 9) 
The CLASI damage score was done on 59/75(78.6%)  patients who had specific 
lesions of LE. The mean CLASI damage score was 8.24 ± 7.55 (range1 to 30) out of the 
maximum  score of 56. The mean number of sites scored for damage was 4.4 (range 1 to 
12).  
 
 
 
 
 
98.3% patients showed dyspigmentation. It was of less than 12 months duration in 
37 (63.79%). The mean number of sites scored for dyspigmentation was 3.22 (range 1 to 
12). Scarring of the skin was seen in 18(24%) patients. The mean number of sites scored 
for scarring were 2.27 (range 1 to 7). 
TABLE 10-SCARRING OF THE SCALP 
Scarring alopecia Grade 3 Grade 4 Grade 5 Grade 6 
Number of patients 
(n=15) 0 4(26.6%) 4(26.6%) 7(46.6%) 
 
Scarring scalp: Grade 3-in one scalp quadrant, Grade 4- in two scalp quadrants, 5- in three scalp 
quadrants, 6-scarring alopecia affecting the whole skull. 
Scarring of the scalp (Table10) 
Scarring of the scalp was seen in 15 patients. 7 (46.6%) had scarring alopecia 
affecting all four quadrants of the scalp. 
14 patients (16.66%) were scored for both scarring and non scarring alopecia as 
the two types of alopecia co-existed in some lesions. 
CLASI activity and damage score was also done in 9 patients who had only 
alopecia and mucosal ulcers without cutaneous involvement. Their CLASI activity score 
ranged from 1 to 3 and the mean was 1.77. It was noted that 5 of these patients had 
moderate to high SLEDAI scores.  The mean SLEDAI scores in these patients were 
11.33± 8.62 (range 2 to 26). 
 
 
 
 
 
 
TABLE 11-SLEDAI PARAMETERS AND THE NUMBER OF PATIENTS 
SLEDAI VARIABLES NUMBER OF PATIENTS 
(n=93) 
PERCENTAGE 
(%) 
Seizures 1 1.07 
Psychosis 0 0 
Organic brain syndrome 4 4.3 
Visual disturbances 0 0 
Cranial nerve disorder 0 0 
Lupus headache 0 0 
Cerebrovascular accident 0 0 
Vasculitis 13 13.97 
Arthritis 18 19.35 
Myositis 5 5.37 
Urinary casts 22 23.65 
Hematuria 25 26.88 
Proteinuria 22 23.65 
Pyuria 22 23.65 
New Rash 55 59.14 
Alopecia 74 79.57 
Mucosal ulcers 39 41.93 
Pleurisy 4 4.3 
Pericarditis 2 2.15 
Low total complement 37 39.78 
Elevated dS DNA 57 61.29 
Leukopenia 13 13.97 
Thrombocytopenia 10 10.75 
Fever 19 20.43 
 
Systemic lupus erythematosus disease activity index (SLEDAI) (Table 11) 
The overall mean SLEDAI score of 93 patients was 13.59 ±7.65 and ranged from 
1 to 32 out of a maximum possible score of 105. The mean SLEDAI score for the 75 
patients with specific lesions of SLE was 13.48 ±7.39 (range 2 to 32) and for the patients 
 
 
 
 
 
in whom CLASI activity score was used was 13.45± 7.43(range 2 to 32). Low (1-5), 
moderate (6-10), high (11-19) and very high (≥20) activity scores were seen in 9 
(12.16%), 23 (31.08%), 26 (35.13%) and 16 (21.62%) patients respectively 
The most commonly scored cutaneous parameter in SLEDAI was alopecia that 
was observed in 79.57% patients. This was followed by an inflammatory type rash 
(specific as well as non-specific LE related) and mucosal ulcers observed in 55 (59.14%) 
and 39 (41.93%) patients respectively. 
Among the systemic manifestations, arthritis was seen in 18 patients (19.35%) 
followed by vasculitis (gangrene, tender finger nodules or biopsy proven vasculitis) in 13 
patients (13.97%).  
Elevation of Anti-ds DNA beyond the reference range of the testing laboratory 
was the most common laboratory parameter seen in 57 patients (61.29%) 
None of the patients had psychoses, visual disturbances, cranial nerve disorders, 
lupus headache or a cerebrovascular accident. 
 
 
 
 
 
 
 
Figure 1 - Distribution of SLEDAI scores 
 
 
Figure 2 - Distribution of CLASI activity scores 
 
 
The CLASI and SLEDAI scores with their mean values less than twice the standard 
distribution have a positively skewed distribution. 
 
Mean = 13.45 
Std. Dev. = 7.438 
N = 74 
Mean = 15.61 
Std. Dev. = 9.29 
N = 74 
 
 
 
 
 
Figure 3-Correlation between CLASI activity score and SLEDAI score 
 
The box and whisker diagram (Figure 3) shows the four groups (1=low, 
2=moderate, 3=high and 4=very high activity) of the SLEDAI severity score represented 
as sledai_gp against the CLASI activity score represented as clasi activity.  The band at 
the middle of the box represents median (50th centile).  The bottom and top of the box are 
the 25th and 75th percentile. The ends of the whiskers represent the maximum and 
minimum values of the data. The distribution of the variables is asymmetric as seen by 
the unequal length of the whiskers and the off centre positions of the median values. With 
increasing SLEDAI severity scores there is no corresponding increase in CLASI activity 
score. 
The correlation between CLASI activity scores and SLEDAI scores did not 
approach statistical significance. (Spearman correlation coefficient r=0.165, p=0.16). 
 
 
 
 
 
 
Figure 4- Correlation between CLASI damage score (clasi_damage) and duration of 
disease (dur_disease) 
 
Figure 5-Correlation between CLASI damage score (clasi_damage) and duration of 
skin lesions (dur_slesion) 
 
 
 
 
 
 
 
The scatter plots (Figures 4,5) display values for CLASI damage score that is the 
dependent variable and the duration of the disease and the duration of skin lesions. The 
data is displayed as a collection of points, each having the value of one variable 
determining the position on the horizontal axis and the value of the other variable 
determining the position on the vertical axis. The pattern of dots slopes from lower left to 
upper right, it suggests a positive correlation between the variables being studied. 
Correlation done between the duration of disease (dur_disease) and CLASI 
damage score (Spearman’s correlation coefficient=0.477) and between the duration of 
skin lesions (dur_slesion) and CLASI damage (Spearman’s correlation 
coefficient=0.472) was statistically significant (p<0.01) 
Linear regression analysis done to quantify the relationship of damage score with 
duration of SLE showed that  for a unit increase in the duration of disease there is a 0.104 
units increase in damage score which was significant at p<0.01. It was also seen that for a 
unit increase in the duration of skin lesion there is a 0.216 units increase in the damage 
score that was also significant at p<0.01. 
 
 
 
 
 
 
 
DISCUSSION 
Cutaneous lupus erythematosus disease area and severity index (CLASI) is a 
relatively new tool formulated in 2005 by American dermatologists at the Veterans 
Affairs Hospital, Philadelphia, USA.2 The CLASI consists of physician rated activity and 
damage scores.  There have been only a few studies done worldwide on the application of 
CLASI in patients with specific lesions of LE in patients with and without systemic 
involvement. Similarly, studies on its applicability in patients of pigmented skin are also 
limited.2,8,19,66 Our aim was to study the applicability of CLASI in specific lesions of 
cutaneous lupus in patients with SLE. We also studied the correlation of the CLASI 
activity score with clinical activity of SLE using the SLEDAI (Systemic lupus 
erythematosus disease activity index), an index used for assessing systemic disease 
activity.4 
This study was done in the Department of Dermatology, Venereology and 
Leprosy.  There were 93 patients recruited in this study which comprised 87 adults and 6 
children. Among the adults, 5 were males and 82 were females.  The  male to female ratio 
of  1:14.5   was similar to a study by Yell J A et al31 and  was much higher than earlier 
studies done in this centre and from Europe where it was 1:713 and 1:5.6 70  respectively. 
Gilliam has classified cutaneous lesions in LE into specific and non-specific 
lesions.3 The prevalence of specific and non-specific cutaneous lesions vary. A study of 
66 patients by  Zecevic R D et al5 showed that more than half the patients with SLE had 
specific lesions. In our study a combination of specific and non-specific lesions was seen 
in 60.21% patients. The most common specific cutaneous lesions in this study were 
discoid lesions that were seen in 51(54.83%) patients followed by malar rash in 29 
 
 
 
 
 
patients (31.19%) and generalised acute cutaneous LE in 26 patients (27.9%). Cardinali C 
et al 27 in their retrospective study on 58 Italian patients with SLE found that discoid 
lesions, ACLE lesions and SCLE were seen in 32.75%, 39.65% and 13.79% of  cases 
respectively. In the Hopkins Lupus cohort of 570 patients, the most common specific 
cutaneous manifestation was malar rash seen in 64% of the patients.1  In a study done on 
32 patients of SLE from this centre, discoid lesions were seen in 21.8%,  maculopapular 
rash in 46.8% and  malar erythema in 34.3% patients.13 
The most prevalent non-specific lesion in our study was alopecia (63.44%) 
followed by oral ulcers (41.93%) and palpable purpura (19.36%). The prevalence of LE 
non-specific lesions in a study by Cardinali C et al was 31% and the most common lesion 
in their patient series was Raynaud’s phenomenon.27 In a review of cutaneous disease 
among 73 SLE patients by Yell JA et al 31 the prevalence of alopecia was lower (54%)  
than  in our series.  Oral ulcers were seen in 41.93% of our patients that was comparable 
to the frequency in the Hopkins cohort.1  
CLASI is reportedly an excellent scoring tool to assess the activity of cutaneous 
lupus.  The most severely affected lesions within each  anatomical area of the body is 
scored.  Serial assessment of the activity and damage using CLASI is useful in studying 
the outcome of therapy as has been shown in a study by Kreuter A et al.19  In this cross 
sectional study, the physician rated CLASI activity and damage score was done on 75 
patients.  Previous studies have been done on limited number of patients ranging from 8-
14 patients.2, 8, 19, 66  
We applied CLASI activity scoring to 74 SLE patients who had specific lesions. 
Five (6.75%) out of 74 patients had only skin involvement.  The mean CLASI activity 
 
 
 
 
 
scores in our patients was 15.6 (range 2-39).  This score was comparable to that seen in 
other studies.19,72 The range of CLASI activity score done in a recent pilot study 
analysing the impact of therapy on the CLE disease severity and the quality of life at time 
of entry in the study was 8-4972  while Kreuter A et al 19 reported the activity scores 
ranging from 5-25 in a study done on patients with SCLE.  
  The parameters that are used to assess the activity of CLE are erythema, 
scale/hypertrophy, mucous membrane involvement, acute hair loss, or non-scarring 
alopecia.62 CLASI activity score is largely based on the extent of the erythema. The latter 
is prominent, easily recognised and can be reliably assessed even in black skin .62  
Erythema was an easily recognizable feature in our patients too. 56.6% patients had  
grade I (pink, faint) and 34.54% patients had grade II (red) erythema.  Only 8.86% 
patients had a grade III erythema (dark red, violaceous, crusted or hemorrhagic).  
Erythema was best appreciated on the face including the malar area. 
Grade I scaling was appreciated in  100% patients whereas hypertrophic scaling 
was seen only in 5 (6.75%) patients. The latter was seen on lesions over the scalp, nose, 
arms and legs.  Scaling was a common feature of lesions on the ears . 
Among the other parameters scored to assess activity, mucosal ulcers were seen in 
more than 50% patients, sixty-one (82.43%) patients had self reported alopecia and non-
scarring alopecia was present in 62 (83.78%) patients. 
  The factors affecting the CLASI activity score in our patients were studied.    
In SLE it has been reported that the number of different types of skin lesions is 
highly indicative of disease activity so that the severity of disease increases with the 
 
 
 
 
 
number of lesions.5 A similar observation was made in our study in relation to specific 
skin lesions of LE. It was found that the activity score increased proportionately with the 
number of anatomical areas involved. In our study, higher CLASI activity scores were 
also seen in patients with SCLE and ACLE occurring in combination with other specific 
lesions as compared to those with only discoid lesions. The five patients who had only 
specific skin lesions without alopecia or mucosal involvement had lower mean CLASI 
activity score compared to those who in addition had the latter two parameters.  
The CLASI damage score was done on 59 out of the 75 patients. The parameters 
in the CLASI damage score are: dyspigmentation, cutaneous scarring /atrophy/ 
panniculitis  and scarring of the scalp. The damage score in our patients ranged from 1 to 
30. The CLASI damage score was studied for its correlation with the duration of SLE and 
the duration of the skin lesions.  A statistically significant correlation was seen with the 
duration of SLE and the duration of skin lesions (p<0.01).  It was also found that for a 
unit increase in the duration of the disease and of skin lesions there was a proportionate 
increase in the damage score. 
SLEDAI was developed by Bombardier C et al at the University of Toronto.4 It is 
a global index containing 24 weighted objective clinical and laboratory variables and 
measures disease activity within the last 10 days.  The maximum possible score is 105.  
The advantage of SLEDAI is the relative small number of items and the ease of scoring.  
Systemic disease activity categories have been defined on the basis of SLEDAI scores: no 
activity (SLEDAI = 0), mild activity (SLEDAI = 1-5), moderate activity (SLEDAI = 6-
10), high activity (SLEDAI = 11-19), and very high activity (SLEDAI 20 and above).69     
We chose SLEDAI to assess the systemic disease activity in view of the simplicity 
 
 
 
 
 
of use.  The SLEDAI activity score of our patients varied from 2 to 32. Low (1-5), 
moderate (6-10), high (11-19) and very high (≥20) activity scores were seen in 9 
(12.16%), 23 (31.08%), 26 (35.13%) and 16 (21.62%) patients respectively.  16 (21.62%) 
patients had a SLEDAI score of greater than 20 that indicated very high disease activity. 
Majority of patients had high disease activity with the SLEDAI scores between 12 to 19.  
Correlation between SLEDAI and CLASI activity scores 
The indices such as BILAG,6 SLAM7 and SLEDAI4 developed to assess systemic 
disease activity in SLE have mucocutaneous manifestations as one of the scoring 
parameters. The mean SLEDAI score of our patients with only specific lesions (11.42) 
was lower than those with only non-specific lesions (14.65) and those with combined 
lesions.  However this did not reach statistical significance. When the CLASI activity 
scores were correlated with SLEDAI, it was found that there was no upward trend in 
CLASI activity score with increasing SLEDAI scores.  This may be in part because the 
cutaneous parameters in the SLEDAI scoring comprise alopecia, mucosal ulcers and a 
new rash. While the former two parameters are a part of activity assessment in CLASI, 
the new rash in SLEDAI score does not specify the type of lesions. It signifies any new 
onset or recurrence of inflammatory rash. The inflammatory rash could signify the 
specific lesions of LE, purpura or urticaria. Secondly, the SLEDAI parameters that have 
been present at the first patient visit or in the preceding 10 days are scored.  Hence an 
inflammatory rash that persisted beyond this duration would not be scored. The mucosal 
involvement in CLASI is scored irrespective of duration while there is a limited time 
frame of 10 days in the SLEDAI scoring. Similarly, the alopecia in CLASI is defined as 
recent hair loss occurring within the last 30 days or as reported by patient, in contrast to 
new onset or recurrence of hair loss in the past 10 days that defines alopecia in SLEDAI. 
 
 
 
 
 
This study was performed on patients with SLE as this group is associated with 
significant morbidity. The skin lesions of SLE may be a pointer to systemic involvement 
and increased disease activity.5 To the best of our knowledge, no study of a similar nature 
has been done in India.  The present study shows that CLASI is applicable in our patients.  
All parameters of the activity and damage scores could be assessed in our patients.  The 
patients with ACLE and SCLE in combination with other specific lesions and those with 
diffuse involvement had greater CLASI activity scores.  We also found that there was a 
positive linear correlation between the CLASI damage score and the duration of SLE and 
of skin lesions (p<0.01).  Although CLASI and SLEDAI are reportedly good scoring 
systems to assess activity of cutaneous and systemic activity respectively we were unable 
to establish a positive correlation between the two in this study (p=0.16). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONCLUSIONS 
1. This study has shown that CLASI is an effective tool to assess cutaneous activity 
and damage of specific lesions of LE. The mean CLASI activity score was 15.6 
(range 2 to 39) and the mean damage score was 8.24 (range 1 to 30).  The scores 
seen in our patients were comparable to other studies. 
2. The mean CLASI activity scores were higher in those who had higher number of 
anatomical sites affected and those with SCLE, and ACLE occurring in 
combination with other specific lesions. 
3. The CLASI damage scores correlated with the duration of SLE (p<0.01) and also 
with the duration of skin lesions (p<0.01).  
4. The correlation of CLASI activity score and the SLEDAI score was poor 
 
 
 
 
 
(p=0.16). 
5. The mean SLEDAI scores of patients with non-specific lesions were higher than 
those with specific lesions. 
 
 
 
 
 
 
SUMMARY 
The study was a prospective, cross sectional study done in the Department of 
Dermatology Venereology and Leprosy from 1st May 2007 to 30th August 2008 (16 
months).  Ninety-three patients satisfied the inclusion criteria.  The mean age of the 
patients was 29.8 ± 12.73 years (range 5-65 years).  The male to female ratio was 1:14.5.  
LE specific lesions were seen in 80.65% and LE non-specific lesions were seen in 78.5% 
patients. Discoid lesions were seen in 51(54.83%) patients followed by malar rash in 29 
patients (31.19%) and generalised acute cutaneous LE in 26 patients (27.9%).  The 
common LE non-specific lesions seen in this study were alopecia (63.4%), mucosal ulcers 
(41.9%) and palpable purpura (19.3%).  CLASI was applied to 75 patients with LE 
specific lesions. The activity and damage scoring was done in 74 and 59 patients 
respectively. The mean CLASI activity score was 15.6 ± 9.28. (range 2 – 39) and the 
damage score was 8.24 ± 7.55 (range 1 – 30).  Patients with diffuse cutaneous 
involvement had higher activity scores. Higher mean CLASI activity scores were also 
seen in patients with SCLE, and ACLE occurring in combination with other specific 
lesions.  The patients with long standing disease and skin lesions had higher damage 
scores (p<0.01). SLEDAI scores ranging from low (1-5), moderate (6-10), high (11-19) 
and very high (≥20) were seen in 9 (12.16%), 23 (31.08%), 26 (35.13%) and 16 (21.62%) 
patients respectively. The mean SLEDAI score for the 75 patients with specific lesions of 
SLE was 13.48 ± 7.43 (range 2 – 32).  The correlation between CLASI activity and 
SLEDAI did not reach statistical significance (p=0.16). 
 
 
 
 
 
 
 
LIMITATIONS 
1. All patients included in this study had prior disease modifying treatment.  CLASI 
activity scores may have been higher if patients were not on prior treatment. 
2. As CLASI scoring is designed for specific lesions, it could not be applied to co-
existing non-specific lesions and to LE-specific lesions like tumid lesions. 
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